Helena Tayton-Martin
Gründer bei ADAPTIMMUNE THERAPEUTICS PLC
Vermögen: 318 060 $ am 30.04.2024
Aktive Positionen von Helena Tayton-Martin
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ADAPTIMMUNE THERAPEUTICS PLC | Corporate Officer/Principal | 15.03.2017 | - |
Gründer | 01.01.2008 | - | |
Geschäftsführer | 01.01.2008 | 15.03.2017 | |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Direktor/Vorstandsmitglied | - | - |
Geschäftsführer | 17.09.2009 | - | |
Gründer | 01.01.2008 | - | |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | Präsident | - | - |
Unternehmenssekretär | - | - |
Karriereverlauf von Helena Tayton-Martin
Ehemalige bekannte Positionen von Helena Tayton-Martin
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TRILLIUM THERAPEUTICS | Direktor/Vorstandsmitglied | 01.10.2017 | 17.11.2021 |
Independent Dir/Board Member | 01.10.2017 | 17.11.2021 | |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Geschäftsführer | 01.01.2008 | 01.01.2017 |
Gründer | 01.01.2008 | 01.01.2017 | |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Corporate Officer/Principal | - | - |
Ausbildung von Helena Tayton-Martin
London Business School | Masters Business Admin |
University of Bristol | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 6 |
Vereinigte Staaten | 3 |
Kanada | 2 |
Operativ
Chief Operating Officer | 3 |
Founder | 3 |
Director/Board Member | 2 |
Sektoral
Health Technology | 5 |
Health Services | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
Private Unternehmen | 5 |
---|---|
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Health Services |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Health Technology |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Health Technology |
Trillium Therapeutics ULC
Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | Health Services |
- Börse
- Insiders
- Helena Tayton-Martin
- Erfahrung